ClinicalTrials.gg
RecruitingNCT07280312Updated Feb 3, 2026

Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions

An interventional study of Transvaginal Ultrasound and Ultrasound Microvessel Imaging in Female Reproductive System Adnexal Neoplasm, Ovarian Carcinoma and Female Reproductive System Neoplasm, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-03.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Ovarian Neoplasms by Mayo Clinic — 5 open to participants now, 8 under way, none of them phase 3. Ovarian Neoplasms · Mayo Clinic.

Planned enrollment
5th of 23
40 · median 27
Started
2026
the only one that year
No phase
2 of 27
1 open now
Registered
26th of 27
by date

Among the 27 studies in Ovarian Neoplasms by Mayo Clinic, this one is the 5th largest by planned enrollment of the 23 interventional ones that give a count, is the only one that started in 2026, is one of 2 with no phase, and was the 26th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

5 of the 27 studies in Ovarian Neoplasms by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Ovarian Neoplasms by Mayo Clinic, or all of them as a file.
02

Study summary

This clinical trial studies how well ultrasound microvessel imaging (UMI) works in evaluating ovarian and adnexal lesions in patients who are scheduled to have surgical treatment for their ovarian or adnexal lesions as part of their clinical care. Ovarian cancer is the most lethal gynecologic malignancy, often diagnosed at an advanced stage. Current diagnostic tools include a blood test (serum cancer antigen 125 [CA125]) and transvaginal ultrasound. However, CA125 has limited diagnostic accuracy and is Food and Drug Administration-approved only for monitoring the return of cancer (recurrence), not for preoperative diagnosis. A key measurement in calculating ovarian and adnexal cancer risk is by looking at increased blood flow, which may suggest a higher risk of cancer developing. However, current ultrasound techniques have limited ability to assess blood flow. A new ultrasound technique, UMI, may have higher sensitivity for detecting small blood vessels compared to traditional ultrasound imaging.

03

Conditions studied

  • Female Reproductive System Adnexal Neoplasm
  • Ovarian Carcinoma
  • Female Reproductive System Neoplasm
  • Ovarian Neoplasms
  • Adnexal Lesion
  • Ovarian Lesion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients aged ≥ 18 years
  • Scheduled for surgery for ovarian or adnexal lesions

Exclusion criteria

Exclusion Criteria:

  • Prior surgical removal of ovarian or adnexal lesions
  • Undergoing chemotherapy or targeted systemic therapy
  • Vulnerable populations, including prisoners, adults lacking capacity to consent, and pregnant women (our study coordinator will ask participants if they are pregnant; if uncertain, a urine pregnancy test will be offered at no cost).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Diagnostic (UMI, transvaginal ultrasound)

    Patients undergo UMI during standard transvaginal ultrasound imaging procedure on study.

    Procedure: Transvaginal Ultrasound · Procedure: Ultrasound Microvessel Imaging

Interventions

  • ProcedureTransvaginal Ultrasound

    Undergo transvaginal ultrasound

    Also known as: transvaginal sonography, TVS, TVU

  • ProcedureUltrasound Microvessel Imaging

    Undergo UMI

    Also known as: 3D Ultrasound Microvessel Imaging, UMI

06

What researchers measure

Primary outcomes

  1. Change in O-RADS score

    Ovarian-Adnexal Reporting and Data System (O-RADS) scores will be initially based on B-mode and Doppler imaging (standard of care) obtained prior to surgical treatment. Radiologists will then review ultrasound microvessel imaging (UMI) images and may choose to revise the score. Accuracy of score adjustments will be assessed using final pathology results from the participant's medical record.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2027, 22 months after the start.

Of 284 non-industry interventional studies with no phase under Ovarian Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 76. This study's planned 22 months is below that.

Counting every sponsor, half of 295 studies reached it within 46 months; a quarter within 23 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2025
First posted
Dec 12, 2025
StartActual
Jan 22, 2026
Primary completionEst.
Dec 17, 2027
CompletionEst.
Dec 17, 2029
Last update
Feb 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07280312
Lead sponsor
Mayo Clinic
Responsible party
Sponsor
First posted
Dec 12, 2025
Start date
Jan 22, 2026
Primary completion
Dec 17, 2027 (estimated)
Completion
Dec 17, 2029 (estimated)
Last update
Feb 3, 2026

Study contacts

Clinical Trials Referral Office
Contact
mayocliniccancerstudies@mayo.edu
855-776-0015
Shigao D. Chen, PhD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion